Bleeding disorders registry for blood-clotting conditions
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You receive care at a participating hemophilia treatment center
- You have hemophilia A
- OR you have hemophilia B
- OR you have von Willebrand disease
- There are no listed exclusion criteria for this registry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry (a large database) that collects information from people who have or may have a blood disorder. It helps researchers learn more about these conditions and improve care.
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
This study looks at cardiovascular problems and blood-clot events (like deep vein clots or pulmonary embolism) in adults with Von Willebrand disease in western France. It may help doctors better understand who is at risk and how to manage these complications.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.